More broadly, whereas the endogenous NIS expression demonstrated in breast tumors can facilitate radioiodine uptake (6, 7) and multiple tumors can be engineered to do so, uptake in these cancers is currently inadequate for effective therapeutic efficacy (8). Here, SLC5A5 is linked to breast neoplasm.